Login to Your Account

Phase I NHL data lift Epizyme as investors await solid tumor data

By Jennifer Boggs
Managing Editor

Monday, June 22, 2015
Three months after regaining global rights to EZH2 inhibitor tazemetostat, Epizyme Inc. presented updated phase I data demonstrating a deepening response rate over time in patients with advanced B-cell non-Hodgkin lymphoma and reiterated plans to advance into phase II testing in NHL and in solid tumors that are INI1-deficient.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription